The FIND-CKD trial delivers three critical findings for clinical practice. First, finerenone achieves a meaningful 14% reduction in heart attacks and strokes among non-diabetic chronic kidney disease patients, addressing a previously under-treated population. Second, this cardiovascular protection extends consistently across all kidney disease stages and underlying causes, demonstrating broad applicability regardless of disease etiology. Third, the medication’s side effect profile remains manageable with appropriate clinical monitoring, particularly regarding hyperkalemia risk. These findings support finerenone’s addition to standard care protocols that already include ACE inhibitors or angiotensin receptor blockers. Clinicians managing non-diabetic chronic kidney disease patients should consider incorporating finerenone into their therapeutic armamentarium, particularly for those with albuminuria and elevated cardiovascular risk, while ensuring appropriate electrolyte monitoring protocols are in place.
Read the full article on GMJ Newsroom.
Was this article helpful?
